story of the week
Abiraterone Acetate Plus Prednisone for Chemotherapy-Naive Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
Abiraterone Acetate Plus Prednisone Versus Placebo Plus Prednisone in Chemotherapy-Naive Men With Metastatic Castration-Resistant Prostate Cancer (COU-AA-302): Final Overall Survival Analysis of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study
Lancet Oncol 2015 Jan 15;[EPub Ahead of Print], CJ Ryan, MR Smith, K Fizazi, F Saad, PF Mulders, CN Sternberg, K Miller, CJ Logothetis, ND Shore, EJ Small, J Carles, TW Flaig, ME Taplin, CS Higano, P de Souza, JS de Bono, TW Griffin, P De Porre, MK Yu, YC Park, J Li, T Kheoh, V Naini, A Molina, DE RathkopfAdvanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.